describe and express emotions), both of which are targeted by CREST, showed improvements after 10 individual sessions of therapy. Social anhedonia and alexithymia were chosen as targets due to the ...
GlobalData on MSN8d
Pfizer’s Phase III bladder cancer therapy trial meets primary endpointPfizer's Phase III trial of sasanlimab with BCG in subjects with BCG-naïve, high-risk NMIBC, has met its primary endpoint.
Sasanlimab (PF-06801591) added to BCG therapy significantly improved outcomes for patients with BCG-naive, high-risk ...
These findings represent the first significant advance in BCG-naïve, high-risk NMIBC therapy in over 30 years. Results from CREST will be presented at an upcoming medical conference. The phase 3 CREST ...
The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.
Pfizer Inc. (NYSE:PFE) released topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational ...
Pfizer (PFE) announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback